midazolam has been researched along with verapamil in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (15.09) | 18.2507 |
| 2000's | 23 (43.40) | 29.6817 |
| 2010's | 18 (33.96) | 24.3611 |
| 2020's | 4 (7.55) | 2.80 |
| Authors | Studies |
|---|---|
| Giacomini, KM; Schaner, ME; Zhang, L | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Evans, CA; Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abd Rabo Moustafa, MM; Abdelghany, TM; Eissa, IH; Elshafeey, A; Mayhoub, AS; Mohammad, H; Qassem, OA; Seleem, MN; Younis, W | 1 |
| Chibale, K; Egan, TJ; Hunter, R; Joshi, MC; Ndove, J; Nsumiwa, S; Okombo, J; Taylor, D; Wiesner, L | 1 |
| Chen, D; Goh, WH; Soh, CK; Wang, H | 1 |
| Dubrovskyi, O; Dye, K; Gutgesell, LM; Huang, F; Li, Y; Ratia, K; Shen, Z; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J | 1 |
| Acevedo, O; Dasararaju, G; Devadasan, V; Halakova, D; Jayaprakash, V; Kovacikova, L; Mohd Siddique, MU; Mondal, SK; Prnova, MS; Shilkar, D; Stefek, M; Thakur, A; Yasmin, S | 1 |
| Kumar, GN; McMillan, JM; Thornburg, KR; Walle, T; Walle, UK | 1 |
| Aranko, K; Backman, JT; Himberg, JJ; Neuvonen, PJ; Olkkola, KT | 1 |
| Beck, WT; Schuetz, EG; Schuetz, JD | 1 |
| Fukuda, T; Hasegawa, R; Murakami, T; Nagai, J; Takano, M; Yumoto, R | 1 |
| Klotz, U | 1 |
| Orszulak-Michalak, D; Owczarek, J; Wiktorowska, A | 1 |
| Iga, T; Kotaki, H; Matsuo, H; Sawada, Y; Takedomi, S; Yamamoto, K; Yamano, K | 1 |
| Murakami, T; Nagai, J; Nasu, R; Sanemasa, M; Takano, M; Yumoto, R | 1 |
| Achira, M; Ito, K; Sugiyama, Y; Suzuki, H | 1 |
| Charman, WN; Johnson, BM; Porter, CJ | 1 |
| Kohno, Y; Suzuki, A; Yamamoto, T | 1 |
| Cook, CS; Fitzloff, JF; Shen, L | 1 |
| Hall, SD; Jones, DR; Wang, YH | 1 |
| Harju, K; Ketola, RA; Kostiainen, R; Kotiaho, T; Salo, PK; Salomies, H; Yli-Kauhaluoma, J | 1 |
| Damron, DS; Kanaya, N; Murray, PA | 1 |
| Nwagwu, CI; Westhout, FD | 1 |
| Boulenc, X; Hachad, H; Levy, RH; Ragueneau-Majlessi, I; Rauch, C | 1 |
| Blasco, H; Bouzom, F; Cazade, F; Chenel, M; Perdaems, N; Vinson, C; Whalley, S | 1 |
| Cao, Y; Jusko, WJ | 1 |
| Barter, Z; Jamei, M; Neuhoff, S; Rostami-Hodjegan, A; Turner, DB; Yeo, KR | 1 |
| Liu, L; Liu, X; Sai, Y; Wang, D; Wang, J; Xia, S; Xue, W | 1 |
| Aspeslet, LJ; Foster, RT; Freitag, DG; Huizinga, RB; Larouche, R; Ling, SY; Mayo, PR | 1 |
| Liu, L; Liu, X; Tang, X; Wang, S; Xu, J; Yang, T; Zhang, J | 1 |
| Chan, LN; Chen, KF; Lin, YS | 1 |
| Alrubia, S; Barber, J; Chen, Y; Mao, J; Rostami-Hodjegan, A | 1 |
3 review(s) available for midazolam and verapamil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Effect of age on pharmacokinetics and pharmacodynamics in man.
Topics: Adolescent; Adult; Aged; Aging; Anti-Anxiety Agents; Area Under Curve; Calcium Channel Blockers; Humans; Injections, Intravenous; Midazolam; Middle Aged; Verapamil | 1998 |
Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs.
Topics: Administration, Oral; ATP Binding Cassette Transporter, Subfamily B; Biological Availability; Crohn Disease; Cytochrome P-450 CYP3A; Humans; Membrane Transport Proteins; Midazolam; Models, Biological; Proteomics; RNA, Messenger; Verapamil | 2022 |
2 trial(s) available for midazolam and verapamil
| Article | Year |
|---|---|
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
Topics: Administration, Oral; Adult; Diltiazem; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Half-Life; Humans; Midazolam; Psychomotor Performance; Verapamil | 1994 |
Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcineurin Inhibitors; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Drug Interactions; Female; Humans; Ketoconazole; Male; Midazolam; Middle Aged; Verapamil | 2014 |
48 other study(ies) available for midazolam and verapamil
| Article | Year |
|---|---|
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
Topics: Carrier Proteins; Corticosterone; HeLa Cells; Humans; Membrane Proteins; Midazolam; Organic Cation Transporter 1; Permeability; Recombinant Proteins; Structure-Activity Relationship; Tetraethylammonium Compounds; Transfection | 1998 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
Topics: Animals; Biometry; Dogs; Drug Evaluation, Preclinical; Haloperidol; Haplorhini; Humans; Injections, Intravenous; Liver; Liver Circulation; Metabolic Clearance Rate; Mifepristone; Molecular Structure; Molecular Weight; Rats; Reproducibility of Results | 2006 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Caenorhabditis elegans; Carbanilides; Drug Resistance, Bacterial; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; Staphylococcus aureus; Vancomycin Resistance | 2017 |
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
Topics: Administration, Oral; Aminopyridines; Aminoquinolines; Animals; Antimalarials; Cell Membrane Permeability; Chloroquine; CHO Cells; Cricetulus; Drug Evaluation, Preclinical; Drug Resistance, Microbial; ERG1 Potassium Channel; Hemeproteins; Humans; Malaria; Male; Mice, Inbred BALB C; Plasmodium berghei; Plasmodium falciparum; Solubility; Structure-Activity Relationship | 2017 |
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Fulvestrant; Humans; MCF-7 Cells; Mice; Models, Molecular; Piperazines; Protein Domains; Pyridines; Pyridones; Receptors, Estrogen; Tissue Distribution; Transcription Factors; Xenograft Model Antitumor Assays | 2020 |
Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
Topics: Aldehyde Reductase; Animals; Caco-2 Cells; Catalytic Domain; Dogs; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Madin Darby Canine Kidney Cells; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Protein Binding; Rats, Wistar; Structure-Activity Relationship; Thiazolidinediones | 2021 |
Taxol metabolism in rat hepatocytes.
Topics: Animals; Cells, Cultured; Chromatography, High Pressure Liquid; Kinetics; Liver; Male; Mass Spectrometry; Midazolam; Paclitaxel; Phenacetin; Rats; Verapamil | 1993 |
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Blotting, Northern; Cell Line; Clotrimazole; Colonic Neoplasms; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Dexamethasone; DNA Primers; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Midazolam; Mixed Function Oxygenases; Molecular Sequence Data; Multigene Family; Phenobarbital; Phenytoin; Polymerase Chain Reaction; Rifampin; Tumor Cells, Cultured; Verapamil | 1996 |
Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.
Topics: Anti-Bacterial Agents; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Caco-2 Cells; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Erythromycin; GABA Modulators; Humans; Ketoconazole; Midazolam; Oxidoreductases, N-Demethylating; Rhodamine 123; Substrate Specificity; Vasodilator Agents; Verapamil | 1998 |
The influence of lidocaine and verapamil on haemodynamic parameters after intravenous administration of midazolam in rabbits.
Topics: Anesthetics, Intravenous; Animals; Anti-Arrhythmia Agents; Blood Pressure; Cardiac Output; Female; Heart Rate; Hemodynamics; Injections, Intravenous; Lidocaine; Male; Midazolam; Rabbits; Stroke Volume; Vascular Resistance; Verapamil | 1999 |
Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver.
Topics: Animals; Blood Proteins; Diltiazem; Drug Interactions; Erythromycin; Hypnotics and Sedatives; Liver; Male; Midazolam; Protein Binding; Rats; Rats, Sprague-Dawley; Verapamil | 2000 |
Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biliary Tract; Blotting, Western; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Drug Interactions; Erythromycin; Intestinal Absorption; Intestines; Liver; Male; Midazolam; Oxidoreductases, N-Demethylating; Rats; Rats, Wistar; Rhodamine 123; Substrate Specificity; Verapamil | 2001 |
Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cyclosporins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Indans; Intestine, Small; Ketoconazole; Liver; Microsomes; Midazolam; Mixed Function Oxygenases; Piperazines; Verapamil; Vinblastine | 1999 |
Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cyclosporins; Cytochrome P-450 CYP3A; In Vitro Techniques; Intestinal Absorption; Jejunum; Ketoconazole; Male; Midazolam; Models, Biological; Oxidoreductases, N-Demethylating; Permeability; Rats; Rats, Sprague-Dawley; Time Factors; Verapamil | 2003 |
High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method.
Topics: Amiodarone; Animals; Baculoviridae; Binding, Competitive; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diltiazem; Enzyme Inhibitors; Fluorescence; Humans; Inhibitory Concentration 50; Ketoconazole; Miconazole; Midazolam; Propafenone; Quinolines; Recombinant Proteins; Troleandomycin; Verapamil | 2004 |
Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As.
Topics: Aryl Hydrocarbon Hydroxylases; Binding Sites; Calcium Channel Blockers; Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; In Vitro Techniques; Kinetics; Mass Spectrometry; Microsomes, Liver; Midazolam; Nifedipine; Oxidoreductases, N-Demethylating; Stereoisomerism; Testosterone; Verapamil | 2004 |
Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
Topics: Blotting, Western; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dealkylation; DNA, Complementary; Enzyme Inhibitors; Humans; Hydroxytestosterones; In Vitro Techniques; Iron; Kinetics; Microsomes, Liver; Midazolam; Stereoisomerism; Verapamil | 2005 |
Analysis of small molecules by ultra thin-layer chromatography-atmospheric pressure matrix-assisted laser desorption/ionization mass spectrometry.
Topics: Atmospheric Pressure; Chromatography, Thin Layer; Metoprolol; Midazolam; Models, Molecular; Molecular Weight; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Verapamil | 2005 |
Effects of L-type Ca2+ channel modulation on direct myocardial effects of diazepam and midazolam in adult rat ventricular myocytes.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Calcium; Calcium Channels, L-Type; Diazepam; Dose-Response Relationship, Drug; Heart Ventricles; Midazolam; Myocytes, Cardiac; Rats; Sarcoplasmic Reticulum; Verapamil | 2006 |
Intra-arterial verapamil-induced seizures: case report and review of the literature.
Topics: Adult; Anticonvulsants; Aphasia, Broca; Carotid Artery, Internal; Female; Functional Laterality; Humans; Injections, Intra-Arterial; Midazolam; Neurosurgical Procedures; Seizures; Subarachnoid Hemorrhage; Vascular Surgical Procedures; Vasodilator Agents; Vasospasm, Intracranial; Verapamil | 2007 |
Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Databases, Factual; Drug Interactions; Enzyme Inhibitors; Erythromycin; Fluconazole; Ketoconazole; Midazolam; Substrate Specificity; Verapamil | 2007 |
Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
Topics: Algorithms; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Ketoconazole; Metabolic Clearance Rate; Midazolam; Models, Biological; Monte Carlo Method; Verapamil | 2010 |
Applications of minimal physiologically-based pharmacokinetic models.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; beta-Lactams; Biological Availability; Carbamates; Codeine; Humans; Kinetics; Liver; Midazolam; Models, Biological; Piperidines; Regional Blood Flow; Verapamil | 2012 |
Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
Topics: Adjuvants, Anesthesia; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B; Computer Simulation; Digoxin; Drug Interactions; Enzyme Inhibitors; Humans; Midazolam; Models, Biological; Permeability; Rifampin; Verapamil | 2013 |
A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human.
Topics: Calcium Channel Blockers; Cyclosporine; Cytochrome P-450 CYP3A; Drug Interactions; Gastric Mucosa; Humans; Intestine, Small; Liver; Microsomes, Liver; Midazolam; Models, Biological; Simvastatin; Stereoisomerism; Verapamil | 2013 |
Predicted contributions of cytochrome P450s to drug metabolism in human liver microsomes using relative activity factor were dependent on probes.
Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Diclofenac; Humans; Kinetics; Microsomes, Liver; Midazolam; Protein Isoforms; Testosterone; Tolbutamide; Verapamil; Warfarin | 2019 |
PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
Topics: Acetaminophen; Administration, Oral; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Biological Availability; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Gastric Bypass; Gastrointestinal Absorption; Hepatobiliary Elimination; Humans; Intestinal Elimination; Metabolic Clearance Rate; Midazolam; Models, Biological; Obesity, Morbid; Postoperative Period; Triazoles; Verapamil | 2020 |